Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 6.3% – Still a Buy?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA)’s share price rose 6.3% on Friday . The company traded as high as $3.21 and last traded at $3.19. Approximately 1,267,020 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 2,772,484 shares. The stock had previously closed at $3.00.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Canaccord Genuity Group raised their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies presently has a consensus rating of “Buy” and an average target price of $6.63.

Taysha Gene Therapies Trading Up 8.0 %

The business’s 50-day moving average price is $2.02 and its two-hundred day moving average price is $2.38. The company has a market capitalization of $664.01 million, a P/E ratio of 5.13 and a beta of 0.44. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of hedge funds and other institutional investors have recently made changes to their positions in TSHA. Geode Capital Management LLC boosted its position in shares of Taysha Gene Therapies by 23.7% during the third quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock worth $7,163,000 after purchasing an additional 682,273 shares in the last quarter. Wellington Management Group LLP bought a new stake in Taysha Gene Therapies in the 3rd quarter valued at $931,000. Bank of New York Mellon Corp bought a new stake in Taysha Gene Therapies in the 2nd quarter valued at $1,018,000. Los Angeles Capital Management LLC bought a new stake in Taysha Gene Therapies in the 3rd quarter valued at $416,000. Finally, Barclays PLC lifted its position in Taysha Gene Therapies by 356.0% in the 3rd quarter. Barclays PLC now owns 247,280 shares of the company’s stock valued at $513,000 after acquiring an additional 193,046 shares in the last quarter. 77.70% of the stock is owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.